Draft Guideline for Prevention and Control of Infections in Neonatal Intensive Care Unit Patients: Draft Recommendations for the Prevention and Control of Staphylococcus aureus in Neonatal Intensive Care Unit Patients

Published date03 September 2019
Citation84 FR 46014
Record Number2019-18907
SectionNotices
CourtCenters For Disease Control And Prevention
Federal Register, Volume 84 Issue 170 (Tuesday, September 3, 2019)
[Federal Register Volume 84, Number 170 (Tuesday, September 3, 2019)]
                [Notices]
                [Page 46014]
                From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
                [FR Doc No: 2019-18907]
                -----------------------------------------------------------------------
                DEPARTMENT OF HEALTH AND HUMAN SERVICES
                Centers for Disease Control and Prevention
                [Docket No. CDC-2019-0077]
                Draft Guideline for Prevention and Control of Infections in
                Neonatal Intensive Care Unit Patients: Draft Recommendations for the
                Prevention and Control of Staphylococcus aureus in Neonatal Intensive
                Care Unit Patients
                AGENCY: Centers for Disease Control and Prevention (CDC), Department of
                Health and Human Services (HHS).
                ACTION: Notice with comment.
                -----------------------------------------------------------------------
                SUMMARY: The Centers for Disease Control and Prevention (CDC), in the
                Department of Health and Human Services (HHS), announces the opening of
                a docket to obtain comment on the Draft Guideline for Prevention and
                Control of Infections in Neonatal Intensive Care Unit Patients: Draft
                Recommendations for the Prevention and Control of Staphylococcus aureus
                in Neonatal Intensive Care Unit Patients (``Draft Guideline''). The
                Draft Guideline provides new, evidence-based recommendations specific
                to the prevention and control of Staphylococcus aureus (S. aureus),
                including methicillin-resistant S. aureus (MRSA) and methicillin-
                sensitive S. aureus (MSSA), in neonatal intensive care unit (NICU)
                patients.
                DATES: Written comments must be received on or before November 4, 2019.
                ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
                0077, by any of the following methods:
                 Federal eRulemaking Portal: http://www.regulations.gov.
                Follow the instructions for submitting comments.
                 Mail: Division of Healthcare Quality Promotion, National
                Center for Emerging and Zoonotic Infectious Diseases, Centers for
                Disease Control and Prevention, Attn: Docket No. CDC-2019-0077, HICPAC
                Secretariat, 1600 Clifton Rd. NE, Mailstop A07, Atlanta, Georgia 30329.
                 Instructions: Submissions via http://regulations.gov are preferred.
                All submissions received must include the agency name and Docket
                Number. All relevant comments received will be posted without change to
                http://regulations.gov, including any personal information provided.
                For access to the docket to read background documents or comments
                received, go to http://www.regulations.gov.
                FOR FURTHER INFORMATION CONTACT: Kendra Cox, Division of Healthcare
                Quality Promotion, National Center for Emerging and Zoonotic Infectious
                Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road
                NE, Mailstop A-07, Atlanta, Georgia 30329; Telephone: (404) 639-4000.
                SUPPLEMENTARY INFORMATION:
                Public Participation
                 Interested persons or organizations are invited to participate by
                submitting written views, recommendations, and data.
                 Please note that comments received, including attachments and other
                supporting materials, are part of the public record and are subject to
                public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your
                comment or supporting materials that you consider confidential or
                inappropriate for public disclosure. If you include your name, contact
                information, or other information that identifies you in the body of
                your comments, that information will be on public display. CDC will
                review all submissions and may choose to redact, or withhold,
                submissions containing private or proprietary information such as
                Social Security numbers, medical information, inappropriate language,
                or duplicate/near duplicate examples of a mass-mail campaign. CDC will
                carefully consider all comments submitted in preparation of the final
                Guideline for Prevention and Control of Infections in Neonatal
                Intensive Care Unit Patients and may revise the final document as
                appropriate.
                Background
                 The Draft Guideline, located in the ``Supporting & Related
                Material'' tab of the docket, provides new, evidence-based
                recommendations specific to the prevention and control of S. aureus,
                including MRSA and MSSA, in NICU patients, including active
                surveillance testing and decolonization.
                 The Draft Guideline is intended for use by infection prevention
                staff, healthcare epidemiologists, healthcare administrators, nurses,
                neonatologists, other healthcare providers, and persons responsible for
                developing, implementing, and evaluating infection prevention and
                control programs for NICUs. The guideline can also serve as a resource
                for societies or organizations to develop more detailed implementation
                guidance for the prevention of infection in NICU patients.
                 The Healthcare Infection Control Practices Advisory Committee
                (HICPAC) worked with national partners, academicians, public health
                professionals, healthcare providers, and other partners to develop this
                Draft Guideline. HICPAC includes representatives from public health,
                infectious diseases, regulatory and other federal agencies,
                professional societies, and other stakeholders.
                 The draft recommendations in this Draft Guideline are informed by a
                systematic review of the best available literature through February
                2017 and of relevant references published since February 2017 suggested
                by subject matter experts. The Appendix, located in the ``Supporting &
                Related Material'' tab of the docket, contains search strategies,
                Evidence Tables containing study-level data examined, and GRADE Tables
                which aggregate the overall strength and direction of the evidence.
                 This Draft Guideline will not be a federal rule or regulation.
                 Dated: August 28, 2019.
                Sandra Cashman,
                Executive Secretary, Centers for Disease Control and Prevention.
                [FR Doc. 2019-18907 Filed 8-30-19; 8:45 am]
                 BILLING CODE 4163-18-P
                

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT